Scientists from the Novartis Institutes for Biomedical Research have retrospectively validated the idea that patient-derived xenografts of tumors are better preclinical models to study cancer drug responses than cell lines. Previous experiments have shown that such xenografts accurately recapitulated drug responses and resistance mechanisms in patients, but few such models have been established.